Insmed, Inc. $INSM Holdings Decreased by HighMark Wealth Management LLC

HighMark Wealth Management LLC decreased its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 95.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 250 shares of the biopharmaceutical company’s stock after selling 5,500 shares during the quarter. HighMark Wealth Management LLC’s holdings in Insmed were worth $44,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. CoreCap Advisors LLC purchased a new position in shares of Insmed during the fourth quarter valued at $27,000. GraniteShares Advisors LLC purchased a new position in shares of Insmed during the fourth quarter valued at $30,000. CIBC Private Wealth Group LLC grew its holdings in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares in the last quarter. SBI Securities Co. Ltd. grew its holdings in shares of Insmed by 404.9% during the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 166 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its holdings in shares of Insmed by 169.7% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 151 shares in the last quarter.

Insiders Place Their Bets

In other Insmed news, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $143.97, for a total value of $1,540,335.03. Following the completion of the sale, the chief executive officer owned 301,185 shares of the company’s stock, valued at $43,361,604.45. The trade was a 3.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Alexander Smith sold 19,638 shares of the business’s stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $150.98, for a total value of $2,964,945.24. Following the completion of the sale, the insider directly owned 51,871 shares of the company’s stock, valued at $7,831,483.58. This represents a 27.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 161,193 shares of company stock valued at $25,462,012 over the last quarter. Insiders own 2.10% of the company’s stock.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $117.99 on Thursday. Insmed, Inc. has a fifty-two week low of $64.85 and a fifty-two week high of $212.75. The business has a 50-day moving average of $142.77 and a two-hundred day moving average of $163.95. The stock has a market capitalization of $25.57 billion, a P/E ratio of -20.52 and a beta of 0.89. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. During the same quarter in the previous year, the firm earned ($1.42) earnings per share. The business’s quarterly revenue was up 229.7% compared to the same quarter last year. On average, equities research analysts predict that Insmed, Inc. will post -2.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on INSM shares. Bank of America boosted their target price on Insmed from $211.00 to $213.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. HC Wainwright restated a “buy” rating on shares of Insmed in a research note on Friday, May 8th. Royal Bank Of Canada lowered their target price on Insmed from $220.00 to $205.00 and set an “outperform” rating on the stock in a research note on Friday, May 8th. Roth Mkm restated a “buy” rating and issued a $212.00 target price on shares of Insmed in a research note on Friday, April 17th. Finally, Morgan Stanley upgraded Insmed from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $166.00 to $212.00 in a research note on Monday, March 30th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $210.95.

Key Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Insmed reported first-quarter 2026 revenue of $306.0 million, driven by BRINSUPRI sales of $207.9 million and ARIKAYCE revenue of $98.1 million. BRINSUPRI revenue jumped 44% sequentially from Q4 2025, reinforcing confidence that the new product launch is gaining traction. Article Title
• Positive Sentiment: The stock also got support from bargain-hunting after falling to a 10-month low earlier in the week, which helped fuel a sharp rebound in the share price. Article Title
• Neutral Sentiment: At the Bank of America Global Healthcare Conference, Insmed presented an update, but the transcript did not include a clear new catalyst in the headline information provided. Article Title
• Negative Sentiment: HC Wainwright trimmed several future EPS estimates for Insmed, including FY2027, FY2028, FY2029, FY2030, and Q4 2026, which may temper enthusiasm about the pace of longer-term profitability even though the firm kept a Buy rating. MarketBeat coverage

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.